Efficacy of low-dose i.v. iron therapy in haemodialysis patients

Nephrology

Volumn 14, Issue 8, 2009, Pages 716-721

  Park, Jung Sik ^b   Park, Jongha ^a   Chang, Jai Won ^b   Lee, Jong Soo ^a   Chung, Hyun Chul ^a   Yang, Won Seok ^b   Lee, Sang Koo ^b   Park, Su Kil ^b  

^a Ulsan University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Anaemia; Erythropoietin; Ferritin; Haemodialysis; Iron

Indexed keywords

EPOKINE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; IRON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG; VENOFERRUM;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 71449108674     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01094.x     Document Type: Article

References (23)

1. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am. J. Kidney Dis. 1995 25 : 433 9.
2. Dunea G, Swagel MA, Bodiwala U, Arruda JA. Intra-dialytic oral iron therapy. Int. J. Artif. Organs 1994 17 : 261 4.
3. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995 26 : 41 6.
4. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996 50 : 1694 9.
5. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001 60 : 2406 11.
6. Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ. Protocolized anemia management with erythropoietin in hemodialysis patients: A randomized controlled trial. J. Am. Soc. Nephrol. 2003 14 : 2654 61.
7. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am. J. Kidney Dis. 2001 37 : S182 238.
8. Lindsay RM, Burton JA, Edward N, Dargie HJ, Prentice CR, Kennedy AC. Dialyzer blood loss. Clin. Nephrol. 1973 1 : 29 34.
9. Longnecker RE, Goffinet JA, Hendler ED. Blood loss during maintenance hemodialysis. ASAIO Trans. 1974 20A : 135 40.
10. Kalender B, Mutlu B, Ersoz M, Kalkan A, Yilmaz A. The effects of acute phase proteins on serum albumin, transferrin and haemoglobin in haemodialysis patients. Int. J. Clin. Pract. 2002 56 : 505 8.
11. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circ. 2002 106 : 2212 17.
12. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005 68 : 1337 43.
13. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996 72 : 413 17.
14. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 1996 11 : 1079 83.
15. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J. 1996 23 : 319 23, discussion 24-5.
16. KDOQI. Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am. J. Kidney Dis. 2006 47 : S11 145.
17. Canavese C, Bergamo D, Ciccone G et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004 65 : 1091 8.
18. Cavaillon JM, Poignet JL, Fitting C, Delons S. Serum interleukin-6 in long-term hemodialyzed patients. Nephron 1992 60 : 307 13.
19. Mandolfo S, Malberti F, Farina M et al. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure. Nephrol. Dial. Transplant. 1998 13 : 2708 9.
20. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin. Dial. 2006 19 : 146 51.
21. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol. Dial. Transplant. 2001 16 : 1416 23.
22. Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr. Opin. Nephrol. Hypertens. 1994 3 : 620 5.
23. Canavese C, Bergamo D, Ciccone G et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol. Dial. Transpl. 2004 19 : 1564 70.